Omics and Cardiometabolic Disease Risk Prediction

Area of Science:

• Cardiovascular and Metabolic Research
• Biomarker Discovery and Translation
• Genomics, Proteomics, and Metabolomics

Background:

• Cardiometabolic disease (CMD) risk assessment is crucial for prevention and management.
• Traditional risk factors do not identify all individuals who develop CMD.
• Novel biomarkers are needed to enhance CMD risk prediction accuracy.

Purpose of the Study:

• To review omic technologies (genomics, proteomics, metabolomics) for cardiometabolic risk assessment.
• To highlight the potential of omics-derived biomarkers in refining disease risk prediction.
• To discuss challenges and opportunities in translating omics findings into clinical practice.

Main Methods:

• Review of select omic technologies and their application in cardiometabolic risk prediction studies.
• Analysis of how omics data provide orthogonal measures of cardiometabolic risk.
• Examination of existing literature on the translation of omics biomarkers to clinical settings.

Main Results:

• Omic technologies offer novel insights into CMD development mechanisms.
• Omics-based biomarkers show potential to improve risk stratification beyond conventional methods.
• Significant hurdles exist in the clinical adoption and implementation of omics findings.

Conclusions:

• Omic technologies represent a promising frontier for advancing cardiometabolic disease risk prediction.
• Further research and strategic approaches are necessary to overcome translational challenges.
• Integrating omics biomarkers into clinical practice could significantly enhance CMD prevention and management.